Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease
Open Access
- 23 August 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 1977
Abstract
Treatment of Mycobacterium abscessus pulmonary infection requires long-term administration of multiple antibiotics. Little is known, however, about the impact of each antibiotic on treatment outcomes. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of antibiotics administered in 244 cases of M. abscessus pulmonary disease. Only 110 (45.1%) patients met the criteria for treatment success. The efficacy of treating M. abscessus pulmonary disease continues to be unsatisfactory especially for infections involving M. abscessus subsp. abscessus. Treatment with drug combinations that included amikacin [adjusted odds ratio (AOR), 3.275; 95% confidence interval (CI), 1.221–8.788], imipenem (AOR, 2.078; 95% CI, 1.151–3.753), linezolid (AOR, 2.231; 95% CI, 1.078–4.616), or tigecycline (AOR, 2.040; 95% CI, 1.079–3.857) was successful. Adverse side effects affected the majority of patients (192/244, 78.7%). Severe effects that resulted in treatment modification included: gastrointestinal distress (29/60, 48.3%) mostly caused by tigecycline, ototoxicity (14/60, 23.3%) caused by amikacin; and myelosuppression (6/60, 10%) caused mainly by linezolid. In conclusion, the success rate of treatment of M. abscessus pulmonary disease is still unsatisfactory. The administration of amikacin, imipenem, linezolid, and tigecycline correlated with increased treatment success. Adverse side effects are common due to long-term, combination antibiotic therapy. Ototoxicity, gastrointestinal distress, and myelosuppression are the most severe.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81672063, 81800003)
This publication has 35 references indexed in Scilit:
- Bactericidal and intracellular activity of β-lactams againstMycobacterium abscessusJournal of Antimicrobial Chemotherapy, 2016
- Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales, AustraliaPathology, 2015
- Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infectionsJournal of Antimicrobial Chemotherapy, 2014
- Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection modelJournal of Antimicrobial Chemotherapy, 2014
- Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial DiseaseAnnals of the American Thoracic Society, 2014
- The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative studyEuropean Respiratory Journal, 2013
- Mycobacterium abscessus: a new antibiotic nightmareJournal of Antimicrobial Chemotherapy, 2012
- In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessusInternational Journal of Antimicrobial Agents, 2007
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Intrapulmonary penetration of linezolidJournal of Antimicrobial Chemotherapy, 2003